Radiopharm Theranostics Limited
RADX · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $3,633 | $299 | $292 | $9 |
| % Growth | 1,114.3% | 2.3% | 3,210.6% | – |
| Cost of Goods Sold | $3,594 | $0 | $0 | $0 |
| Gross Profit | $39 | $299 | $292 | $9 |
| % Margin | 1.1% | 100% | 100% | 100% |
| R&D Expenses | $27,515 | $17,559 | $13,800 | $4,125 |
| G&A Expenses | $16,526 | $15,218 | $13,021 | $10,848 |
| SG&A Expenses | $16,526 | $15,218 | $13,021 | $10,848 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$5,828 | $4,143 | $7,979 | $4,953 |
| Operating Expenses | $38,213 | $36,920 | $34,800 | $19,925 |
| Operating Income | -$38,174 | -$36,621 | -$34,508 | -$19,916 |
| % Margin | -1,050.6% | -12,238.4% | -11,803.3% | -225,527.7% |
| Other Income/Exp. Net | -$65 | -$11,232 | -$65 | -$10,378 |
| Pre-Tax Income | -$38,239 | -$47,853 | -$34,573 | -$30,295 |
| Tax Expense | $103 | $96 | $38 | $44 |
| Net Income | -$38,342 | -$47,949 | -$34,611 | -$30,339 |
| % Margin | -1,055.3% | -16,024.3% | -11,838.6% | -343,550.9% |
| EPS | -5.28 | -36 | -33 | -29.76 |
| % Growth | 85.3% | -9.1% | -10.9% | – |
| EPS Diluted | -5.28 | -36 | -33 | -29.76 |
| Weighted Avg Shares Out | 6,937 | 1,288 | 1,019 | 1,019 |
| Weighted Avg Shares Out Dil | 6,937 | 1,288 | 1,019 | 1,019 |
| Supplemental Information | – | – | – | – |
| Interest Income | $888 | $50 | $145 | $0 |
| Interest Expense | $65 | $643 | $86 | $9,350 |
| Depreciation & Amortization | $7 | $3,126 | $3,297 | $2,981 |
| EBITDA | -$38,167 | -$44,084 | -$31,191 | -$17,963 |
| % Margin | -1,050.4% | -14,732.4% | -10,668.6% | -203,412.5% |